ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Blood Cancer Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Published Date: September 2024
|
Report Code: QYRE-Auto-35P6785
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Blood Cancer Drugs Market Insights and Forecast to 2028
BUY CHAPTERS

Blood Cancer Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Code: QYRE-Auto-35P6785
Report
September 2024
Pages:115
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Amgen Inc
Astrazeneca plc
Astellas Pharma
Bayer
Bristol Myers Squibb Company
Celgene Corporation
Eli Lilly
F.Hoffmann-La Roche
Johnson & Johnson
Novartis
Pfizer Inc
Takeda Pharmaceutical Company Ltd
AbbVie

Blood Cancer Drugs - Market Size

The global market for Blood Cancer Drugs was estimated to be worth US$ 62740 million in 2023 and is forecast to a readjusted size of US$ 91940 million by 2030 with a CAGR of 5.5% during the forecast period 2024-2030

Blood Cancer Drugs - Market

Blood Cancer Drugs - Market

Blood cancers, or hematologic cancers, affect the production and function of blood cells. Most of these cancers start in the bone marrow where blood is produced.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Blood Cancer Drugs, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Blood Cancer Drugs by region & country, by Type, and by Application.
The Blood Cancer Drugs market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Blood Cancer Drugs.
Market Segmentation

Scope of Blood Cancer Drugs - Market Report

Report Metric Details
Report Name Blood Cancer Drugs - Market
Forecasted market size in 2030 US$ 91940 million
CAGR 5.5%
Forecasted years 2024 - 2030
Segment by Type:
Segment by Application
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Amgen,, AstraZeneca PLC,, Astellas Pharma,, Bayer AG,, Bristol-Myers Squibb Company,, Celgene Corporation,, Eli Lilly,, F.Hoffmann-La Roche,, Johnson & Johnson,, Novartis, Pfizer,, Takeda Pharmaceutical Company Ltd,, AbbVie
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 2: Detailed analysis of Blood Cancer Drugs manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 5: Revenue of Blood Cancer Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 6: Revenue of Blood Cancer Drugs in country level. It provides sigmate data by Type, and by Application for each country/region.
  • Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
  • Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 9: Conclusion.

FAQ for this report

What is the Blood Cancer Drugs - Market size in 2030?

Ans: The Blood Cancer Drugs - Market size in 2030 will be US$ 91940 million.

Who are the main players in the Blood Cancer Drugs - Market report?

Ans: The main players in the Blood Cancer Drugs - Market are Amgen,, AstraZeneca PLC,, Astellas Pharma,, Bayer AG,, Bristol-Myers Squibb Company,, Celgene Corporation,, Eli Lilly,, F.Hoffmann-La Roche,, Johnson & Johnson,, Novartis, Pfizer,, Takeda Pharmaceutical Company Ltd,, AbbVie

What are the Application segmentation covered in the Blood Cancer Drugs - Market report?

Ans: The Applications covered in the Blood Cancer Drugs - Market report are Leukemia, lymphoma, Multiple Myeloma

What are the Type segmentation covered in the Blood Cancer Drugs - Market report?

Ans: The Types covered in the Blood Cancer Drugs - Market report are Blood Chemotherapy Drugs, Blood Targeted Therapy Drugs

Recommended Reports

Blood Cancer Therapy

Cancer Drug Markets

Related Hematology Markets

1 Market Overview
1.1 Blood Cancer Drugs Product Introduction
1.2 Global Blood Cancer Drugs Market Size Forecast
1.3 Blood Cancer Drugs Market Trends & Drivers
1.3.1 Blood Cancer Drugs Industry Trends
1.3.2 Blood Cancer Drugs Market Drivers & Opportunity
1.3.3 Blood Cancer Drugs Market Challenges
1.3.4 Blood Cancer Drugs Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Blood Cancer Drugs Players Revenue Ranking (2023)
2.2 Global Blood Cancer Drugs Revenue by Company (2019-2024)
2.3 Key Companies Blood Cancer Drugs Manufacturing Base Distribution and Headquarters
2.4 Key Companies Blood Cancer Drugs Product Offered
2.5 Key Companies Time to Begin Mass Production of Blood Cancer Drugs
2.6 Blood Cancer Drugs Market Competitive Analysis
2.6.1 Blood Cancer Drugs Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Blood Cancer Drugs Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Blood Cancer Drugs as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Blood Chemotherapy Drugs
3.1.2 Blood Targeted Therapy Drugs
3.2 Global Blood Cancer Drugs Sales Value by Type
3.2.1 Global Blood Cancer Drugs Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Blood Cancer Drugs Sales Value, by Type (2019-2030)
3.2.3 Global Blood Cancer Drugs Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Leukemia
4.1.2 lymphoma
4.1.3 Multiple Myeloma
4.2 Global Blood Cancer Drugs Sales Value by Application
4.2.1 Global Blood Cancer Drugs Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Blood Cancer Drugs Sales Value, by Application (2019-2030)
4.2.3 Global Blood Cancer Drugs Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Blood Cancer Drugs Sales Value by Region
5.1.1 Global Blood Cancer Drugs Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Blood Cancer Drugs Sales Value by Region (2019-2024)
5.1.3 Global Blood Cancer Drugs Sales Value by Region (2025-2030)
5.1.4 Global Blood Cancer Drugs Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Blood Cancer Drugs Sales Value, 2019-2030
5.2.2 North America Blood Cancer Drugs Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Blood Cancer Drugs Sales Value, 2019-2030
5.3.2 Europe Blood Cancer Drugs Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Blood Cancer Drugs Sales Value, 2019-2030
5.4.2 Asia Pacific Blood Cancer Drugs Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Blood Cancer Drugs Sales Value, 2019-2030
5.5.2 South America Blood Cancer Drugs Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Blood Cancer Drugs Sales Value, 2019-2030
5.6.2 Middle East & Africa Blood Cancer Drugs Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Blood Cancer Drugs Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Blood Cancer Drugs Sales Value
6.3 United States
6.3.1 United States Blood Cancer Drugs Sales Value, 2019-2030
6.3.2 United States Blood Cancer Drugs Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Blood Cancer Drugs Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Blood Cancer Drugs Sales Value, 2019-2030
6.4.2 Europe Blood Cancer Drugs Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Blood Cancer Drugs Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Blood Cancer Drugs Sales Value, 2019-2030
6.5.2 China Blood Cancer Drugs Sales Value by Type (%), 2023 VS 2030
6.5.3 China Blood Cancer Drugs Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Blood Cancer Drugs Sales Value, 2019-2030
6.6.2 Japan Blood Cancer Drugs Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Blood Cancer Drugs Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Blood Cancer Drugs Sales Value, 2019-2030
6.7.2 South Korea Blood Cancer Drugs Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Blood Cancer Drugs Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Blood Cancer Drugs Sales Value, 2019-2030
6.8.2 Southeast Asia Blood Cancer Drugs Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Blood Cancer Drugs Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Blood Cancer Drugs Sales Value, 2019-2030
6.9.2 India Blood Cancer Drugs Sales Value by Type (%), 2023 VS 2030
6.9.3 India Blood Cancer Drugs Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Amgen,
7.1.1 Amgen, Profile
7.1.2 Amgen, Main Business
7.1.3 Amgen, Blood Cancer Drugs Products, Services and Solutions
7.1.4 Amgen, Blood Cancer Drugs Revenue (US$ Million) & (2019-2024)
7.1.5 Amgen, Recent Developments
7.2 AstraZeneca PLC,
7.2.1 AstraZeneca PLC, Profile
7.2.2 AstraZeneca PLC, Main Business
7.2.3 AstraZeneca PLC, Blood Cancer Drugs Products, Services and Solutions
7.2.4 AstraZeneca PLC, Blood Cancer Drugs Revenue (US$ Million) & (2019-2024)
7.2.5 AstraZeneca PLC, Recent Developments
7.3 Astellas Pharma,
7.3.1 Astellas Pharma, Profile
7.3.2 Astellas Pharma, Main Business
7.3.3 Astellas Pharma, Blood Cancer Drugs Products, Services and Solutions
7.3.4 Astellas Pharma, Blood Cancer Drugs Revenue (US$ Million) & (2019-2024)
7.3.5 Bayer AG, Recent Developments
7.4 Bayer AG,
7.4.1 Bayer AG, Profile
7.4.2 Bayer AG, Main Business
7.4.3 Bayer AG, Blood Cancer Drugs Products, Services and Solutions
7.4.4 Bayer AG, Blood Cancer Drugs Revenue (US$ Million) & (2019-2024)
7.4.5 Bayer AG, Recent Developments
7.5 Bristol-Myers Squibb Company,
7.5.1 Bristol-Myers Squibb Company, Profile
7.5.2 Bristol-Myers Squibb Company, Main Business
7.5.3 Bristol-Myers Squibb Company, Blood Cancer Drugs Products, Services and Solutions
7.5.4 Bristol-Myers Squibb Company, Blood Cancer Drugs Revenue (US$ Million) & (2019-2024)
7.5.5 Bristol-Myers Squibb Company, Recent Developments
7.6 Celgene Corporation,
7.6.1 Celgene Corporation, Profile
7.6.2 Celgene Corporation, Main Business
7.6.3 Celgene Corporation, Blood Cancer Drugs Products, Services and Solutions
7.6.4 Celgene Corporation, Blood Cancer Drugs Revenue (US$ Million) & (2019-2024)
7.6.5 Celgene Corporation, Recent Developments
7.7 Eli Lilly,
7.7.1 Eli Lilly, Profile
7.7.2 Eli Lilly, Main Business
7.7.3 Eli Lilly, Blood Cancer Drugs Products, Services and Solutions
7.7.4 Eli Lilly, Blood Cancer Drugs Revenue (US$ Million) & (2019-2024)
7.7.5 Eli Lilly, Recent Developments
7.8 F.Hoffmann-La Roche,
7.8.1 F.Hoffmann-La Roche, Profile
7.8.2 F.Hoffmann-La Roche, Main Business
7.8.3 F.Hoffmann-La Roche, Blood Cancer Drugs Products, Services and Solutions
7.8.4 F.Hoffmann-La Roche, Blood Cancer Drugs Revenue (US$ Million) & (2019-2024)
7.8.5 F.Hoffmann-La Roche, Recent Developments
7.9 Johnson & Johnson,
7.9.1 Johnson & Johnson, Profile
7.9.2 Johnson & Johnson, Main Business
7.9.3 Johnson & Johnson, Blood Cancer Drugs Products, Services and Solutions
7.9.4 Johnson & Johnson, Blood Cancer Drugs Revenue (US$ Million) & (2019-2024)
7.9.5 Johnson & Johnson, Recent Developments
7.10 Novartis
7.10.1 Novartis Profile
7.10.2 Novartis Main Business
7.10.3 Novartis Blood Cancer Drugs Products, Services and Solutions
7.10.4 Novartis Blood Cancer Drugs Revenue (US$ Million) & (2019-2024)
7.10.5 Novartis Recent Developments
7.11 Pfizer,
7.11.1 Pfizer, Profile
7.11.2 Pfizer, Main Business
7.11.3 Pfizer, Blood Cancer Drugs Products, Services and Solutions
7.11.4 Pfizer, Blood Cancer Drugs Revenue (US$ Million) & (2019-2024)
7.11.5 Pfizer, Recent Developments
7.12 Takeda Pharmaceutical Company Ltd,
7.12.1 Takeda Pharmaceutical Company Ltd, Profile
7.12.2 Takeda Pharmaceutical Company Ltd, Main Business
7.12.3 Takeda Pharmaceutical Company Ltd, Blood Cancer Drugs Products, Services and Solutions
7.12.4 Takeda Pharmaceutical Company Ltd, Blood Cancer Drugs Revenue (US$ Million) & (2019-2024)
7.12.5 Takeda Pharmaceutical Company Ltd, Recent Developments
7.13 AbbVie
7.13.1 AbbVie Profile
7.13.2 AbbVie Main Business
7.13.3 AbbVie Blood Cancer Drugs Products, Services and Solutions
7.13.4 AbbVie Blood Cancer Drugs Revenue (US$ Million) & (2019-2024)
7.13.5 AbbVie Recent Developments
8 Industry Chain Analysis
8.1 Blood Cancer Drugs Industrial Chain
8.2 Blood Cancer Drugs Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Blood Cancer Drugs Sales Model
8.5.2 Sales Channel
8.5.3 Blood Cancer Drugs Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
FEATURED COMPANIES
Amgen Inc
Astrazeneca plc
Astellas Pharma
Bayer
Bristol Myers Squibb Company
Celgene Corporation
Eli Lilly
F.Hoffmann-La Roche
Johnson & Johnson
Novartis
Pfizer Inc
Takeda Pharmaceutical Company Ltd
AbbVie
List of Tables
    Table 1. Blood Cancer Drugs Market Trends
    Table 2. Blood Cancer Drugs Market Drivers & Opportunity
    Table 3. Blood Cancer Drugs Market Challenges
    Table 4. Blood Cancer Drugs Market Restraints
    Table 5. Global Blood Cancer Drugs Revenue by Company (2019-2024) & (US$ Million)
    Table 6. Global Blood Cancer Drugs Revenue Market Share by Company (2019-2024)
    Table 7. Key Companies Blood Cancer Drugs Manufacturing Base Distribution and Headquarters
    Table 8. Key Companies Blood Cancer Drugs Product Type
    Table 9. Key Companies Time to Begin Mass Production of Blood Cancer Drugs
    Table 10. Global Blood Cancer Drugs Companies Market Concentration Ratio (CR5 and HHI)
    Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Blood Cancer Drugs as of 2023)
    Table 12. Mergers & Acquisitions, Expansion Plans
    Table 13. Global Blood Cancer Drugs Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
    Table 14. Global Blood Cancer Drugs Sales Value by Type (2019-2024) & (US$ Million)
    Table 15. Global Blood Cancer Drugs Sales Value by Type (2025-2030) & (US$ Million)
    Table 16. Global Blood Cancer Drugs Sales Market Share in Value by Type (2019-2024) & (%)
    Table 17. Global Blood Cancer Drugs Sales Market Share in Value by Type (2025-2030) & (%)
    Table 18. Global Blood Cancer Drugs Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
    Table 19. Global Blood Cancer Drugs Sales Value by Application (2019-2024) & (US$ Million)
    Table 20. Global Blood Cancer Drugs Sales Value by Application (2025-2030) & (US$ Million)
    Table 21. Global Blood Cancer Drugs Sales Market Share in Value by Application (2019-2024) & (%)
    Table 22. Global Blood Cancer Drugs Sales Market Share in Value by Application (2025-2030) & (%)
    Table 23. Global Blood Cancer Drugs Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 24. Global Blood Cancer Drugs Sales Value by Region (2019-2024) & (US$ Million)
    Table 25. Global Blood Cancer Drugs Sales Value by Region (2025-2030) & (US$ Million)
    Table 26. Global Blood Cancer Drugs Sales Value by Region (2019-2024) & (%)
    Table 27. Global Blood Cancer Drugs Sales Value by Region (2025-2030) & (%)
    Table 28. Key Countries/Regions Blood Cancer Drugs Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
    Table 29. Key Countries/Regions Blood Cancer Drugs Sales Value, (2019-2024) & (US$ Million)
    Table 30. Key Countries/Regions Blood Cancer Drugs Sales Value, (2025-2030) & (US$ Million)
    Table 31. Amgen, Basic Information List
    Table 32. Amgen, Description and Business Overview
    Table 33. Amgen, Blood Cancer Drugs Products, Services and Solutions
    Table 34. Revenue (US$ Million) in Blood Cancer Drugs Business of Amgen, (2019-2024)
    Table 35. Amgen, Recent Developments
    Table 36. AstraZeneca PLC, Basic Information List
    Table 37. AstraZeneca PLC, Description and Business Overview
    Table 38. AstraZeneca PLC, Blood Cancer Drugs Products, Services and Solutions
    Table 39. Revenue (US$ Million) in Blood Cancer Drugs Business of AstraZeneca PLC, (2019-2024)
    Table 40. AstraZeneca PLC, Recent Developments
    Table 41. Astellas Pharma, Basic Information List
    Table 42. Astellas Pharma, Description and Business Overview
    Table 43. Astellas Pharma, Blood Cancer Drugs Products, Services and Solutions
    Table 44. Revenue (US$ Million) in Blood Cancer Drugs Business of Astellas Pharma, (2019-2024)
    Table 45. Astellas Pharma, Recent Developments
    Table 46. Bayer AG, Basic Information List
    Table 47. Bayer AG, Description and Business Overview
    Table 48. Bayer AG, Blood Cancer Drugs Products, Services and Solutions
    Table 49. Revenue (US$ Million) in Blood Cancer Drugs Business of Bayer AG, (2019-2024)
    Table 50. Bayer AG, Recent Developments
    Table 51. Bristol-Myers Squibb Company, Basic Information List
    Table 52. Bristol-Myers Squibb Company, Description and Business Overview
    Table 53. Bristol-Myers Squibb Company, Blood Cancer Drugs Products, Services and Solutions
    Table 54. Revenue (US$ Million) in Blood Cancer Drugs Business of Bristol-Myers Squibb Company, (2019-2024)
    Table 55. Bristol-Myers Squibb Company, Recent Developments
    Table 56. Celgene Corporation, Basic Information List
    Table 57. Celgene Corporation, Description and Business Overview
    Table 58. Celgene Corporation, Blood Cancer Drugs Products, Services and Solutions
    Table 59. Revenue (US$ Million) in Blood Cancer Drugs Business of Celgene Corporation, (2019-2024)
    Table 60. Celgene Corporation, Recent Developments
    Table 61. Eli Lilly, Basic Information List
    Table 62. Eli Lilly, Description and Business Overview
    Table 63. Eli Lilly, Blood Cancer Drugs Products, Services and Solutions
    Table 64. Revenue (US$ Million) in Blood Cancer Drugs Business of Eli Lilly, (2019-2024)
    Table 65. Eli Lilly, Recent Developments
    Table 66. F.Hoffmann-La Roche, Basic Information List
    Table 67. F.Hoffmann-La Roche, Description and Business Overview
    Table 68. F.Hoffmann-La Roche, Blood Cancer Drugs Products, Services and Solutions
    Table 69. Revenue (US$ Million) in Blood Cancer Drugs Business of F.Hoffmann-La Roche, (2019-2024)
    Table 70. F.Hoffmann-La Roche, Recent Developments
    Table 71. Johnson & Johnson, Basic Information List
    Table 72. Johnson & Johnson, Description and Business Overview
    Table 73. Johnson & Johnson, Blood Cancer Drugs Products, Services and Solutions
    Table 74. Revenue (US$ Million) in Blood Cancer Drugs Business of Johnson & Johnson, (2019-2024)
    Table 75. Johnson & Johnson, Recent Developments
    Table 76. Novartis Basic Information List
    Table 77. Novartis Description and Business Overview
    Table 78. Novartis Blood Cancer Drugs Products, Services and Solutions
    Table 79. Revenue (US$ Million) in Blood Cancer Drugs Business of Novartis (2019-2024)
    Table 80. Novartis Recent Developments
    Table 81. Pfizer, Basic Information List
    Table 82. Pfizer, Description and Business Overview
    Table 83. Pfizer, Blood Cancer Drugs Products, Services and Solutions
    Table 84. Revenue (US$ Million) in Blood Cancer Drugs Business of Pfizer, (2019-2024)
    Table 85. Pfizer, Recent Developments
    Table 86. Takeda Pharmaceutical Company Ltd, Basic Information List
    Table 87. Takeda Pharmaceutical Company Ltd, Description and Business Overview
    Table 88. Takeda Pharmaceutical Company Ltd, Blood Cancer Drugs Products, Services and Solutions
    Table 89. Revenue (US$ Million) in Blood Cancer Drugs Business of Takeda Pharmaceutical Company Ltd, (2019-2024)
    Table 90. Takeda Pharmaceutical Company Ltd, Recent Developments
    Table 91. AbbVie Basic Information List
    Table 92. AbbVie Description and Business Overview
    Table 93. AbbVie Blood Cancer Drugs Products, Services and Solutions
    Table 94. Revenue (US$ Million) in Blood Cancer Drugs Business of AbbVie (2019-2024)
    Table 95. AbbVie Recent Developments
    Table 96. Key Raw Materials Lists
    Table 97. Raw Materials Key Suppliers Lists
    Table 98. Blood Cancer Drugs Downstream Customers
    Table 99. Blood Cancer Drugs Distributors List
    Table 100. Research Programs/Design for This Report
    Table 101. Key Data Information from Secondary Sources
    Table 102. Key Data Information from Primary Sources
    Table 103. Business Unit and Senior & Team Lead Analysts
List of Figures
    Figure 1. Blood Cancer Drugs Product Picture
    Figure 2. Global Blood Cancer Drugs Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 3. Global Blood Cancer Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 4. Blood Cancer Drugs Report Years Considered
    Figure 5. Global Blood Cancer Drugs Players Revenue Ranking (2023) & (US$ Million)
    Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Blood Cancer Drugs Revenue in 2023
    Figure 7. Blood Cancer Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
    Figure 8. Blood Chemotherapy Drugs Picture
    Figure 9. Blood Targeted Therapy Drugs Picture
    Figure 10. Global Blood Cancer Drugs Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 11. Global Blood Cancer Drugs Sales Value Market Share by Type, 2023 & 2030
    Figure 12. Product Picture of Leukemia
    Figure 13. Product Picture of lymphoma
    Figure 14. Product Picture of Multiple Myeloma
    Figure 15. Global Blood Cancer Drugs Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 16. Global Blood Cancer Drugs Sales Value Market Share by Application, 2023 & 2030
    Figure 17. North America Blood Cancer Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 18. North America Blood Cancer Drugs Sales Value by Country (%), 2023 VS 2030
    Figure 19. Europe Blood Cancer Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 20. Europe Blood Cancer Drugs Sales Value by Country (%), 2023 VS 2030
    Figure 21. Asia Pacific Blood Cancer Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 22. Asia Pacific Blood Cancer Drugs Sales Value by Country (%), 2023 VS 2030
    Figure 23. South America Blood Cancer Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 24. South America Blood Cancer Drugs Sales Value by Country (%), 2023 VS 2030
    Figure 25. Middle East & Africa Blood Cancer Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 26. Middle East & Africa Blood Cancer Drugs Sales Value by Country (%), 2023 VS 2030
    Figure 27. Key Countries/Regions Blood Cancer Drugs Sales Value (%), (2019-2030)
    Figure 28. United States Blood Cancer Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 29. United States Blood Cancer Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 30. United States Blood Cancer Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 31. Europe Blood Cancer Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 32. Europe Blood Cancer Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 33. Europe Blood Cancer Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 34. China Blood Cancer Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 35. China Blood Cancer Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 36. China Blood Cancer Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 37. Japan Blood Cancer Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 38. Japan Blood Cancer Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 39. Japan Blood Cancer Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 40. South Korea Blood Cancer Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 41. South Korea Blood Cancer Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 42. South Korea Blood Cancer Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 43. Southeast Asia Blood Cancer Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 44. Southeast Asia Blood Cancer Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 45. Southeast Asia Blood Cancer Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 46. India Blood Cancer Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 47. India Blood Cancer Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 48. India Blood Cancer Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 49. Blood Cancer Drugs Industrial Chain
    Figure 50. Blood Cancer Drugs Manufacturing Cost Structure
    Figure 51. Channels of Distribution (Direct Sales, and Distribution)
    Figure 52. Bottom-up and Top-down Approaches for This Report
    Figure 53. Data Triangulation
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$3950

This license allows only one user to access the PDF.
Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Strategic Venue Partners

SIMILAR REPORTS

Global Blood Cancer Treatments Market Research Report 2024
Global Blood Cancer Therapeutics Market Insights Forecast to 2030
Global Blood and Bone Marrow Cancer Treatment Market Insights Forecast to 2030
Global Blood Tumor Drugs Market Research Report 2024
Global Hematological Cancers Market Research Report 2024
Global Blood Tumor Treatment Market Research Report 2024
Hematologic Malignancies Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Hematology Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Drugs for Hematology Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Blood Cancer Biological Product Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Blood Cancer Detection Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Hematology Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Targeted Drug for Blood Cancers Market Research Report 2024
Hematology Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Hematological Malignancy Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Hematological Malignancies Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Hematologic Oncology Treatment Market Research Report 2024
Myelofibrosis Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Hematologic Malignancies Treatment Market Research Report 2024
Global Hematology Oncology Diagnostics Market Research Report 2024
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions